创新药概念全线扬升 晶泰控股(02228)涨逾14% 机构指创新药仍为行业核心增量

金吾财讯
Jun 29

金吾财讯 | 创新药概念全线扬升,截至发稿,晶泰控股(02228)涨14.07%,康诺亚-B(02162)涨13.27%,荣昌生物(09995)涨13.14%,诺诚健华(09969)涨12.44%,海西新药(02637)涨10.04%,乐普生物(02157)涨9.78%,亚盛医药(06855)涨9.25%,康方生物(09926)涨9.24%,三生制药(01530)涨9.05%,石药集团(01093)涨8.67%。消息面上,华鑫证券新近研究表示,自2015年创新药审批改革开始,创新药逐步成为医药行业的核心增量。以恒瑞医药为代表的创新药企业,创新药的收入比重持续提升。2025年,创新药板块依靠出海为突破口实现了价值的重构,截止目前创新出海的趋势依然非常强劲。根据医药魔方,2026年1季度,中国相关交易总额达614亿美元,约占全球医药交易总金额的70%,已超过2024年全年总和,预计2026全年将突破1500亿美元大关。展望未来,创新药仍将是行业的核心增量,不仅国内医保支出上给予持续的倾斜和保障,还有系列政策持续落地的支持。创新药的利润占比和市值比重提升,也给予了医药行业重要的估值支撑。回顾十一年来医药行业的整体表现,医药行业指数已基本回到2015年年初水平,但创新药指数相对于2019年年初仍有可观的涨幅。2026年以来,创新药指数较年初有一定调整,更多是市场行业偏好的影响。6月份以来,已有药明康德等企业开始公告回购或增持方案,逐步扭转市场对医药行业的信心。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10